卫宁健康 reported revenue of ¥0.99B for the period ended 2026-06-30, +18.5% year on year. Net income was ¥-0.19B, a -19.5% net margin on a 33.7% gross margin. The largest revenue line is 软件及服务 at 83% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.99B | +18.5% |
| Gross profit | ¥0.33B | — |
| Operating income | ¥-0.23B | — |
| Net income | ¥-0.19B | — |
| Gross margin | 33.7% | Net margin -19.5% |
| Revenue Q/Q | +50.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 软件及服务 | ¥0.83B | 83.3% |
| 互联网医疗健康 | ¥0.10B | 10.0% |
| 系统集成 | ¥0.07B | 6.8% |
| 其他(补充) | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.66B | 66.3% |
| R&D | ¥0.17B | 17.3% |
| SG&A | ¥0.27B | 27.0% |
| Tax & other | ¥-0.04B | -3.5% |
| Item | Amount |
|---|---|
| Total assets | ¥8.20B |
| Total liabilities | ¥2.73B |
| Shareholders' equity | ¥5.47B |
| Equity / assets | 66.7% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | -8% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
仟源医药 ・ 常山药业 ・ 星星科技 ・ 开山股份 ・ 精锻科技 ・ 新天科技 ・ 新莱应材 ・ 雅本化学 ・ 隆华科技 ・ 佳创视讯 ・ 通光线缆 ・ 兴源环境
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies